Streetbeat News

ADIL

Adial Pharmaceuticals, Inc.

https://www.adialpharma.com

Industry

Biotechnology

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Open

1.02

Mkt cap

6.9M

Volume

193K

High

1.09

P/E Ratio

-0.27

52-wk high

4.17

Low

1.00

Div yield

N/A

52-wk low

0.77

In Friday's intraday session, several healthcare stocks experienced significant movements. Adial Pharmaceuticals, BioVie, Cardiff Oncology, Myomo, Altamira Therapeutics, and MSP Recovery were among the gainers, with increases ranging from 24.11% to 58.8%. Conversely, Scilex Holding, Precision BioSciences, DermTech, Vivani Medical, Gritstone Bio, and Humacyte saw declines between 20.81% and 36.4%. Notably, Cardiff Oncology and DermTech released their Q4 earnings reports yesterday.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 5:35 pm

U.S. stocks traded mixed with the Dow Jones falling and NASDAQ rising. Dell Technologies reported better-than-expected Q4 results and increased its dividend by 20%. BioVie, Adial Pharmaceuticals, and Nxu saw significant stock price increases due to positive developments. Conversely, GigCapital5, Fisker, and Scilex Holding experienced substantial declines. Oil and gold prices rose, while European and Asian markets were mostly higher.

Portfolio Pulse from Avi Kapoor

March 01, 2024 | 2:47 pm

In Friday's pre-market session, several healthcare stocks showed significant movement. Adial Pharmaceuticals, BioVie, Bone Biologics, Y-mAbs Therapeutics, Cardiff Oncology, and Biodesix experienced notable gains, with increases ranging from 17.53% to 76.0%. On the downside, Scilex Holding, Humacyte, Gritstone Bio, Precision BioSciences, Vivani Medical, and DermTech saw declines between 16.41% and 35.7%. The movements were largely attributed to recent Q4 earnings reports.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 1:09 pm

Butterfly Network, Inc. (BFLY) shares fell by 22% after reporting a larger-than-expected GAAP loss for Q4, despite beating sales estimates. Other stocks experienced significant movements, with Enveric Biosciences, Inc. (ENVB) and Societal CDMO, Inc. (SCTL) among the top gainers, while J-Long Group Limited (JL) and Golden Minerals Company (AUMN) led the losers.

Portfolio Pulse from Avi Kapoor

February 29, 2024 | 7:00 pm

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) shares surged after the company announced receiving a new patent for AD04, aimed at treating opioid use disorder. The patent, awarded by the United States Patent and Trademark Office, covers AD04's ability to target the serotonin transporter gene. CEO Cary Claiborne highlighted the patent's importance for the company's Intellectual Property portfolio and AD04's potential in treating various drug dependencies. Following the announcement, ADIL's stock price increased by 117.5% to $1.89, with trading volume significantly exceeding the 100-day average.

Portfolio Pulse from Erica Kollmann

February 28, 2024 | 7:43 pm

U.S. stocks closed lower with the Dow Jones, NASDAQ, and S&P 500 all experiencing declines. ADT Inc. reported better-than-expected earnings for its fourth quarter, despite a sales decline. Vivani Medical, Adial Pharmaceuticals, and vTv Therapeutics saw significant stock price increases, while Oragenics, Integral Ad Science, and Inogen experienced notable drops. The real estate sector saw gains, whereas communication services declined.

Portfolio Pulse from Avi Kapoor

February 28, 2024 | 7:30 pm

Bumble Inc. shares fell by 11.6% following weak quarterly results, missing both earnings and sales estimates. Other stocks showed significant movement, with Vivani Medical, Adial Pharmaceuticals, and vTv Therapeutics among the top gainers due to positive announcements. Conversely, Oragenics and Integral Ad Science were among the biggest losers, with Oragenics falling after pricing a public offering and Integral Ad Science dropping post-earnings.

Portfolio Pulse from Avi Kapoor

February 28, 2024 | 7:02 pm

Health care stocks experienced significant movements in Wednesday's intraday session. Vivani Medical, Adial Pharmaceuticals, vTv Therapeutics, BioSig Technologies, Imunon, and G1 Therapeutics were among the top gainers, with Vivani Medical leading with a 314.4% increase. On the downside, Oragenics, Palatin Techs, Inogen, Novavax, Vicarious Surgical, and Ocean Biomedical saw notable declines, with Oragenics experiencing the largest drop of 42.9%. G1 Therapeutics and Novavax released their Q4 earnings, impacting their stock movements.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 5:31 pm

Adial Pharmaceuticals' stock price increased following the announcement of a new patent for AD04, aimed at treating opioid use disorder.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 5:29 pm

U.S. stocks traded lower with the Nasdaq down 50 points. Real estate shares rose by 1.1%, while health care shares fell by 0.8%. U.S. crude oil inventories increased more than expected. Vivani Medical, Adial Pharmaceuticals, and vTv Therapeutics saw significant stock price increases, while Oragenics, Integral Ad Science, and Inogen experienced notable declines.

Portfolio Pulse from Avi Kapoor

February 28, 2024 | 5:25 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.